46
Participants
Start Date
September 23, 2025
Primary Completion Date
March 1, 2027
Study Completion Date
December 31, 2029
Lurbinectedin 4 MG Injection [Zepzelca]
Lurbinectedin shall be administered intravenously at a dose of 3.2 mg/m2 over 60 minutes every 21 days. The administration of the study drug shall be continued until disease progression or the occurrence of unacceptable toxicity.
National Cancer Center, Goyang-si
Seoul National University Bundang Hospital
OTHER
Samsung Medical Center
OTHER
Seoul National Hospital
OTHER_GOV
Gangnam Severance Hospital
OTHER
National Cancer Center, Korea
OTHER_GOV